Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Wells Fargo

By Jason Carr

Wells Fargo analyst Jim Birchenough maintained a Buy rating on Crispr Therapeutics AG (CRSPResearch Report) today. The company’s shares closed last Monday at $68.94, close to its 52-week high of $74.00.

According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 19.8% and a 47.8% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Ionis Pharmaceuticals, and Akcea Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $73.81 average price target, implying a 19.0% upside from current levels. In a report issued on November 12, Oppenheimer also upgraded the stock to Buy with a $65.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $74.00 and a one-year low of $22.22. Currently, Crispr Therapeutics AG has an average volume of 533.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.